Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib With or Without Ustekinumab in Crohn's Disease
ChiCTR2600129026Phase 4Completed
- Sponsor
- Subei People's Hospital
- Start
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of upadacitinib and ustekinumab in Crohn's disease (2 arms), sponsored by Subei People's Hospital. Primary endpoints: Clinical response and remission rate at 52 weeks, Endoscopic response and remission rate at 52 weeks and 1 more. Started Jul 2026; status: completed.
02
Drugs
upadacitinibustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2600129026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129026.